Fluoroethylnormemantine - ReST Therapeutics
Alternative Names: FENM - ReST Therapeutics; RST-01Latest Information Update: 04 Sep 2024
At a glance
- Originator ReST Therapeutics
- Class Adamantanes; Amines; Fluorinated hydrocarbons; Neuroprotectants; Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Post-traumatic stress disorders
Most Recent Events
- 04 Sep 2024 Fluoroethylnormemantine - ReST Therapeutics is available for licensing as of 04 Sep 2024. https://www.rest-therapeutics.com/contact/ (ReST Therapeutics website, September 2024)
- 04 Sep 2024 Rest Therapeutics has patents protection for Fluoroethylnormemantine (Rest Therapeutics website, September 2024)
- 04 Sep 2024 ReST Therapeutics announces intention to submit our IND Application in Q3 2024 (ReST Therapeutics pipeline; September 2024)